Wall Street analyst estimates for Bionano Genomics, Inc. (BNGO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 0.57 |
Valuation Ratios
| Price / Book | 0.54 |
| EV / EBITDA | -0.75 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.8M | $9.5M | $12.0M | $10.1M | $8.5M | $18.0M | $27.8M | $36.1M | $30.8M | $28.5M |
| Cost of Revenue | $3.6M | $6.0M | $8.7M | $6.8M | $5.7M | $14.1M | $21.9M | $26.6M | $30.4M | $22.2M |
| Gross Profit | $3.2M | $3.5M | $3.3M | $3.4M | $2.8M | $3.9M | $5.9M | $9.6M | $380000 | $6.3M |
| Research & Development | $11.4M | $12.0M | $9.5M | $9.1M | $10.3M | $22.5M | $49.0M | $54.0M | $24.8M | $11.4M |
| Selling, General & Admin | $13.0M | $14.1M | $14.2M | $20.2M | 0 | $58.5M | $88.6M | $95.0M | $51.9M | $28.2M |
| Operating Expenses | $24.4M | $26.1M | $23.7M | $29.2M | $41.3M | $81.0M | $137.6M | $224.8M | $104.4M | $39.6M |
| Operating Income | -$21.2M | -$23.2M | -$20.4M | -$25.9M | -$38.6M | -$77.1M | -$131.7M | -$215.2M | -$104.0M | -$33.3M |
| EBITDA | -$17.3M | -$21.3M | -$15.8M | -$26.4M | -$35.6M | -$73.9M | -$120.3M | -$213.6M | -$97.5M | -$16.3M |
| Interest Expense | $470072 | $590927 | $1.4M | $2.3M | $2.5M | $927000 | $298000 | $5.1M | $289000 | $298000 |
| Pre-tax Income | -$18.8M | -$23.3M | -$18.5M | -$29.8M | -$41.1M | -$78.2M | -$130.7M | -$232.4M | -$112.0M | -$26.3M |
| Income Tax | $12924 | $18552 | $15511 | $21048 | $29000 | -$5.7M | $1.9M | $62000 | $33000 | $67000 |
| Net Income | -$18.8M | -$23.4M | -$18.5M | -$29.8M | -$41.1M | -$72.4M | -$132.6M | -$232.5M | -$112.0M | -$26.4M |
| EPS | $-1131.43 | $-1402.56 | $-1568.13 | $-1194.36 | $-236.58 | $-157.02 | $-275.09 | $-408.48 | $-88.13 | $-4.85 |
| EPS (Diluted) | $-1131.43 | $-1402.56 | $-1568.13 | $-1194.36 | $-236.58 | $-157.02 | $-275.09 | $-408.48 | $-88.13 | $-4.85 |
| Shares Outstanding (Diluted) | $16659 | $16659 | $11795 | $24963 | $173752 | $461303 | $482016 | $569166 | $1.3M | $5.4M |
Price
| Price | $1.51 |
| Market Cap | $17M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AIM · BNBX · GBS · KTTA · MYNZ · NDRA · POAI
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of BNGO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks